A Detailed Analysis of the Drug Discovery Enzymes Market Based on the Rising Demand for Innovative Solutions in Pharmaceutical Drug Discovery
Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 115
Report ID: PMRREP33955
The global drug discovery enzymes market is forecast to expand at a CAGR of 7.7% and thereby increase from a value of US$1.8 Bn in 2023, to US$3 Bn by the end of 2030.
|
Attributes |
Key Insights |
|
Drug Discovery Enzymes Market Size (2023E) |
US$1.8 Bn |
|
Projected Market Value (2030F) |
US$3.0 Bn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
7.7% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
5.2% |
Drug discovery enzymes constitute a specialized class of enzymes integral to the exploration and creation of novel pharmaceutical compounds. These enzymes play a crucial role in specific functions such as protein engineering, screening, optimization, and drug molecule synthesis. Leveraging drug discovery enzymes empowers scientists to enhance the drug development process by expediting chemical reactions, improving efficiency, and augmenting the overall success rate of drug discovery initiatives. Typically sourced from natural origins like microorganisms or plants, these enzymes showcase exceptional catalytic properties, facilitating the generation of intricate drug molecules.
The market for drug discovery enzymes has witnessed significant expansion in recent years, fueled by the increasing need for innovative drugs and advancements in biotechnology. Enzymes play a vital role in the drug discovery journey, serving as effective tools for target identification, lead optimization, and drug synthesis. This market features numerous key players providing an extensive array of enzyme products and services. The continuous rise in research and development investments, coupled with the growing embrace of enzymatic technologies, is anticipated to drive further growth in the drug discovery enzymes market.
Increasing Disease Burden, and Technological Advancements in Enzyme Engineering
The global prevalence of diseases like cancer, cardiovascular disorders, and infectious diseases has been on a consistent rise. Cancer, a leading cause of global mortality, resulted in nearly 10 million deaths in 2020, representing almost one in six deaths. In low- and lower-middle-income countries, infections such as human papillomavirus (HPV), and hepatitis contribute to approximately 30% of cancer cases. Each year, around 400,000 children are diagnosed with cancer, and the most common types vary across countries, with cervical cancer being predominant in 23 nations. This surge in disease incidence has generated a heightened demand for effective therapeutics, propelling the expansion of the drug discovery enzymes market.
The field of drug discovery enzymes has witnessed significant progress due to notable advancements in enzyme engineering techniques. The creation of new enzyme variants featuring improved catalytic properties and stability has played a crucial role in expediting the identification and optimization of potential drug candidates.
Handling and Safety Hazards Associated with Enzymes
The growth of the market is anticipated to be constrained by challenges related to the handling and safety hazards associated with enzymes, as well as heightened susceptibility to temperature and pH variations. Moreover, the market faces hindrances in terms of elevated financial costs and challenges in recruiting and retaining participants, impeding its overall growth. Furthermore, inadequacies in the clinical research workforce, obstacles imposed by drug sponsors, and issues about the globalization of clinical research are potential factors that may negatively impact market expansion.
Lack of Standardization, and Concerns Around IP Rights
The absence of standardization in enzymatic assays and protocols poses a challenge to result in reproducibility and the comparison of data among various research groups. Initiatives to establish standardized protocols and assay formats are in progress but need additional refinement and widespread adoption. In the drug discovery enzymes market, intellectual property rights wield substantial influence. Securing patent protection for novel enzymes and enzyme-related technologies is essential to stimulate innovation and attract investment. Nevertheless, intricate patent landscapes and the expiration of specific patents can influence market dynamics.
Development of Novel Enzyme Variants, and Growing Integration of AI and ML
Ongoing progress in enzyme engineering techniques presents prospects for creating innovative enzyme variants characterized by improved catalytic properties, stability, and substrate specificity. These developments open doors to new applications and enhance the effectiveness of drug discovery procedures. The incorporation of Artificial Intelligence (AI), and machine learning (ML) technologies into drug discovery holds the potential to transform the field significantly. AI and ML algorithms can predict enzyme properties, optimize enzymatic reactions, and devise novel platforms for enzyme-based drug discovery.
Which is the Top Product Type Segment?
Kinases Secure Top Rank for their Vital Role in Signal Transduction Pathways
Kinases, as enzymes, facilitate the transfer of phosphate groups from ATP to target molecules, predominantly proteins. Their pivotal involvement in signal transduction pathways makes them appealing targets for drug discovery, particularly within the oncology sector.
Which Sector is the Most Prominent End User?
Pharma and Biotech Companies Register Notable Demand Generation
The pharmaceutical and biotechnology sector is experiencing rapid growth within the market, driven by the widespread applications of enzymes. Enzymes are utilized for various purposes, including the synthesis of antimicrobials, dynamic kinetic resolution of drugs, production of APIs, enzyme therapy, and amino acid synthesis. The incorporation of enzymes in drug formulations has paved the way for treating conditions like cancer and AIDS, thereby generating significant opportunities in this segment.
Top Regional Markets
North America Takes the Lead with Significantly High Per Capita Healthcare Expenditure
The North American pharmaceutical and biotechnology industries thrive on early adoption of state-of-the-art technology, driven by significant per capita healthcare expenditures and the introduction of groundbreaking enzyme-based drugs. In 2022, U.S. healthcare spending experienced a 4.1 percent growth, reaching a total of $4.5 trillion, equivalent to $13,493 per person. This expenditure constituted 17.3 percent of the nation's Gross Domestic Product. Beyond their role in digestive aids, advancements in enzyme formulation have been instrumental in discovering novel applications for enzymes within the pharmaceutical sector.
Higher Prevalence of Chronic Diseases to Push Asia Pacific
The region is witnessing increased market growth due to the emergence of new enzymes designed to address various chronic illnesses, coupled with heightened development initiatives by major companies. A significant factor contributing to this growth is the prevalence of chronic diseases in the population, with six in ten Americans living with at least one chronic condition such as heart disease, stroke, cancer, or diabetes. These chronic diseases not only represent leading causes of death and disability but also contribute significantly to healthcare costs. Additionally, the region is experiencing rapid expansion, attributed to the availability of highly skilled labor at cost-effective rates and the implementation of environmental regulations in recent years.
The drug discovery enzymes market is anticipated to undergo substantial expansion and change. It is recommended that industry players proactively pursue partnerships and cooperation with other relevant parties, such as technology suppliers, research institutes, and pharmaceutical companies. These collaborations can help with resource optimization, knowledge exchange, and the creation of creative drug discovery solutions. In the market for drug discovery enzymes, staying up to date with technical developments is essential. Businesses should make investments in the integration of robots, automation, artificial intelligence, and machine learning technologies to boost productivity, strengthen data analysis skills, and quicken the drug discovery process.
Supply-side Dynamics
Several factors, including the Increased disease burden and growing focus on Biopharmaceuticals, all contribute to the dynamic and rapid expansion of the global drug discovery enzymes market. Sigma-Aldrich Co. LLC., Kaneka Corporation, Actelion Pharmaceuticals Ltd, Genesis Biotechnology Group, and Suven Life Sciences Limited are market leaders in the manufacturing sector. The countries of Germany, Japan, China, France, and the United States are significant producers of various goods. The United States has embraced advanced techniques and possesses a well-established infrastructure. Key medications such as Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and others are readily available in the U.S. market.
Several corporations are allocating resources toward expanding their capacity to satisfy the increasing need for advanced technology in the pharmaceutical & biotechnology industries. It is anticipated that these expansions will substantially alter the dynamics of the market, resulting in heightened competition, reduced prices, and an influx of innovative products.
Prominent organizations, including Sigma-Aldrich Co. LLC., Kaneka Corporation, and Actelion Pharmaceuticals Ltd, are at the vanguard of this sector, providing inventive solutions by capitalizing on their technological prowess and vast experience in the Drug industry. Organizations operating within this sector prioritize rigorous research and development endeavors geared towards creating innovative enzymes, refining enzyme engineering techniques, and broadening applications in drug discovery. Market participants are dedicated to augmenting their product portfolios with advanced features, expanding their geographical reach, and cultivating robust relationships with pharmaceutical companies and research institutions.
To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing distinctive attributes, enhanced precision, and adhering to strict regulatory standards and quality assurance to acquire more customers and gain a competitive edge over their rivals.
New Product Launch
In November 2020, Genesis Therapeutics, and Genentech entered into a collaboration for AI-driven, multi-target drug development. This partnership leverages Genesis' expertise in graph machine learning and drug discovery to identify new drug candidates targeting various therapeutic targets across multiple disease categories.
Market Impact: The efficiency and accuracy of finding new medication candidates will probably be improved by Genesis Therapeutics' expertise in graph machine learning and drug discovery technology. Through the use of cutting-edge AI methods, the collaboration aims to expedite the process of finding new drugs by identifying therapeutic targets more quickly across a range of illness categories. Through the introduction of innovative concepts and an increase in the success rate of drug development campaigns, this partnership has the potential to support the expansion of the drug discovery enzymes market.
(Source: Biospace)
In January 2020, Bayer entered into a collaboration with Exscientia, an artificial intelligence-driven drug discovery company. This partnership aims to jointly develop and optimize novel lead structures for potential therapeutic candidates, focusing on the treatment of cardiovascular and oncological diseases.
Market Impact: The drug development process may be sped up by the use of cutting-edge technology like artificial intelligence, which could result in the discovery of enzyme-based solutions with better qualities. Furthermore, the emphasis on creating treatment candidates for cancer and cardiovascular disorders shows a strategic alignment with taking on important health issues. The market for drug discovery enzymes may rise as a result of this partnership's potential to increase the use of these enzymes in the treatment of difficult and prevalent medical disorders.
(Source: Drug Discovery Trends)
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Product Type:
By End-User:
By Region:
To know more about delivery timeline for this report Contact Sales
The market is anticipated to grow at a CAGR of 7.7% during the projected period.
The drug discovery enzymes market was valued at US$1.8 billion in 2023.
The US held the largest market share in 2023.
Some of the prominent players in the market are Sigma-Aldrich Co. LLC., Kaneka Corporation, Actelion Pharmaceuticals Ltd, Genesis Biotechnology Group, and Suven Life Sciences Limited.
The active Kinases segment is expected to grow at the fastest CAGR during the forecast period.
